Aug 20, 2026 · 8 min

SK Hynix rewards investors as AI costs unsettle Asian markets

SK Hynix Up, Kuaishou Plunges, Sino Biopharmaceutical Up

The episode connects corporate capital returns, rising AI expenses, cancer-treatment advances, and urban planning to broader shifts in Asian markets and economies.

3 key takeaways

1SK Hynix shares rose after a $29 billion buyback and stronger shareholder-return plans exceeded investor expectations.
2Kuaishou plunged as weaker profitability and the cost of developing AI businesses overshadowed modest growth in its AI model.
3Asian healthcare stocks gained after Moderna and Merck reported encouraging late-stage results for a personalized melanoma vaccine.

Don't miss

SK Hynix’s $29 billion buyback and upgraded shareholder-return plans trigger the clearest investor reaction in the market roundup.

The brief

SK Hynix leads the market action after announcing a $29 billion buyback and stronger shareholder-return plans, prompting investors to reassess the value of its capital strategy.

Kuaishou offers the counterpoint: weaker profitability and the expense of building AI-focused businesses sent shares lower despite modest growth in its AI model.

Healthcare stocks moved higher after Moderna and Merck reported encouraging late-stage results for a personalized melanoma vaccine, raising hopes of reducing cancer recurrence.

The episode then widens from individual stocks to cities, previewing a discussion of AI, long-term planning and Dubai’s approach to managing rapid population growth.

What was said on this episode

9 statements · 7 positive · 1 negative · 1 neutral

Winnie Sueon SK Hynix future growthPositive1:27
SK Hynix management signals confidence in future company growth.
“management is very confident in terms of of the future growth of the company”
Listen at 1:27
Winnie Sueon Kuaishou AI development costsNegative2:28
High AI-development costs are reducing Kuaishou’s income.
“the high cost of developing AI, AI-centered business is really weighing on the company's income”
Listen at 2:28
Winnie Sueon mRNA-based cancer therapyPositive4:05
The trial is the first positive late-stage trial for an mRNA cancer therapy.
“this is the first time we are seeing a positive late stage trial for any mRNA based cancer therapy”
Listen at 4:05
Winnie Sueon Moderna-Merck personalized melanoma vaccinePositive4:16
The personalized vaccine can be customized to patients’ tumor mutations.
“they can customize the vaccines based on the patient's specific tumor mutations”
Listen at 4:16
Winnie Sueon Moderna sharesPositive4:25
Moderna shares rose 177% after the late-stage trial news.
“Moderna shares up 177% yesterday”
Listen at 4:25
Winnie Sueon Sino Biopharmaceutical sharesPositive4:35
Sino Biopharmaceutical shares rose more than 10%.
“Sino Biopharmaceuticals, for example, up more than 10%”
Listen at 4:35
Winnie Sueon Moderna-Merck personalized melanoma vaccineNeutral4:45
The personalized vaccine requires approval, with a timeline extending to 2027 or later.
“it has to... be approved for now we are looking at the timeline at 2027 plus”
Listen at 4:45
Rohit Krishnanon AI in smart citiesPositive6:01
AI will accelerate processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 6:01
Estefanía Tapiason Dubai urban planningPositive6:29
Dubai has a long-term urban-planning vision.
“They have a long-term urban planning vision”
Listen at 6:29

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Featuring

SCStephen Carroll JGJacob Greaves RKRohit Krishnan ETEstefanía Tapias

Mentioned

SHSK Hynix

Kuaishou

Bloomberg Audio Studios

Books & mentions

Economy at Scale

It extends the episode’s closing discussion of AI, urban innovation and Dubai’s long-term planning.

Listen to the full episode and explore every guest, topic, and moment on PodLume.

Listen to the full episode Or get the iOS app